@article{ART002719608},
author={Mohd Abdul Kayum and Ifra Abdul Qaiyyum and Arzeena Jabeen and Mohammad Nawab},
title={Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)},
journal={CELLMED},
issn={3022-6805},
year={2021},
volume={11},
number={2},
pages={9-9},
doi={10.5667/CellMed.2021.0009}
TY - JOUR
AU - Mohd Abdul Kayum
AU - Ifra Abdul Qaiyyum
AU - Arzeena Jabeen
AU - Mohammad Nawab
TI - Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)
JO - CELLMED
PY - 2021
VL - 11
IS - 2
PB - Cellmed Orthocellular Medicine and Pharmaceutical Association
SP - 9
EP - 9
SN - 3022-6805
AB - Nazla-i-muzmin (Chronic rhinosinusitis) is one of the commonest diseases prevalent all around the world. In India one in eight Indian suffers from this ailment. The current medical management and surgical intervention do not provide complete cure as a result there is a need to search a better alternative drug. The main objective of this study was to evaluate the safety and efficacy of a Unani formulation in the management of chronic rhinosinusitis. This study was designed as a randomised, controlled, parallel group and open label clinical study. It was carried out in 60 participants (30 participants in each group) of chronic rhinosinusitis aged between 18-65 years of either sex. The participants were enrolled based on the symptoms rhinorrhoea, sneezing, facial pain, nasal blockage, post nasal drip and thick nasal discharge. The participants of the test group was treated with a Unani formulation (9 gm) whereas Levocetrizine (10mg) was given to the participants of the control group once at night. In this study the average age of the participants was 30.36 (±10.20) years and 32.63 (±10.97) years in the control and test groups respectively with an average chronicity of 31.26 (± 43.46) months in the control group and 23.86 ± 39.4 months in the test group. The Unani formulation was found effective in reducing rhinorrhoea, sneezing, facial pain, nasal obstruction, post nasal discharge and thick nasal discharge. The snot score at post treatment comparing to the baseline was reduced to 2.1 and 2.0 in the test and control groups respectively. The Unani formulation improved the symptoms of chronic rhinosinusitis in the test group due to the possible action of the ingredients having, deobstruent, anti-inflammatory, concoctive, analgesic, expectorants and antimicrobial activities. It was concluded that the outcome of the study showed the successful management of chronic rhino-sinusitis. The formulation was well tolerated and showed no adverse effect.
KW - deobstruent;nazla-i-muzmin;rhino-sinusitis;sneezing;Unani formulation
DO - 10.5667/CellMed.2021.0009
ER -
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen and Mohammad Nawab. (2021). Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis). CELLMED, 11(2), 9-9.
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen and Mohammad Nawab. 2021, "Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)", CELLMED, vol.11, no.2 pp.9-9. Available from: doi:10.5667/CellMed.2021.0009
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen, Mohammad Nawab "Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)" CELLMED 11.2 pp.9-9 (2021) : 9.
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen, Mohammad Nawab. Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis). 2021; 11(2), 9-9. Available from: doi:10.5667/CellMed.2021.0009
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen and Mohammad Nawab. "Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)" CELLMED 11, no.2 (2021) : 9-9.doi: 10.5667/CellMed.2021.0009
Mohd Abdul Kayum; Ifra Abdul Qaiyyum; Arzeena Jabeen; Mohammad Nawab. Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis). CELLMED, 11(2), 9-9. doi: 10.5667/CellMed.2021.0009
Mohd Abdul Kayum; Ifra Abdul Qaiyyum; Arzeena Jabeen; Mohammad Nawab. Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis). CELLMED. 2021; 11(2) 9-9. doi: 10.5667/CellMed.2021.0009
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen, Mohammad Nawab. Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis). 2021; 11(2), 9-9. Available from: doi:10.5667/CellMed.2021.0009
Mohd Abdul Kayum, Ifra Abdul Qaiyyum, Arzeena Jabeen and Mohammad Nawab. "Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)" CELLMED 11, no.2 (2021) : 9-9.doi: 10.5667/CellMed.2021.0009
